Initiate Phase I/II clinical trial for AMT-162
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 27 Feb 2023
- Due
- 31 Dec 2023
- Delivered
- October 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to initiate a Phase I/II clinical trial in the second half of 2023”
What we found
Evidence strength A What the grades mean
The company planned to initiate the Phase I/II clinical trial for AMT-162 in the second half of 2023, but the first patient was not enrolled until October 2024.
-
A uniQure N.V. 10-K filed 2025-02-27
“we incurred $7.3 million and $6.0 million of expenses, respectively, to initiate a Phase I/II clinical trial in which enrolled the first patient in October 2024.” ✓ confirmed on the page
Market reaction: the shares moved -4.8% against the S&P 500 over the three sessions around the disclosure (26 Feb 2025 to 3 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- AMT-162 Phase I/II trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-QURE-001821 · Corrections policy